AC Immune and Bayer Schering Pharma collaborate in brain imaging for Alzheimer’s Disease

12-Oct-2009 - Switzerland

AC Immune SA announced that it has entered a collaboration with Bayer Schering Pharma on the diagnostic imaging of Alzheimer´s Disease. Bayer´s novel positron emission tomography (PET) tracer florbetaben will be applied for imaging beta-Amyloid plaques in the brain of patients undergoing the Phase I clinical testing of AC Immune´s Alzheimer´s vaccine ACI-24. This is the first time this PET tracer will be tested in treated Alzheimer’s patients.

Prof. Andrea Pfeifer, CEO of AC Immune said, “This collaboration with Bayer adds further value to our Alzheimer´s vaccine ACI-24. The adoption of a diagnostic imaging substance visualizing the deposition of beta-Amyloid that is targeted by our vaccine can be an important parameter for dose selection, and will provide useful complementary data. There is a key trend in the industry to co-develop therapy guiding diagnostics alongside drugs for patients. We look forward to working with Bayer´s experts in this ground-breaking collaboration.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures